BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1978687)

  • 1. A restriction fragment length polymorphism for human topoisomerase II: possible relationship to drug-resistance.
    Zwelling LA; Mayes J; Deisseroth K; Hinds M; Grant G; Pathak S; Ledley FD; Vyas R; Hittelman W
    Cancer Commun; 1990; 2(11):357-61. PubMed ID: 1978687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II.
    Zwelling LA; Hinds M; Chan D; Mayes J; Sie KL; Parker E; Silberman L; Radcliffe A; Beran M; Blick M
    J Biol Chem; 1989 Oct; 264(28):16411-20. PubMed ID: 2550442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II.
    Hinds M; Deisseroth K; Mayes J; Altschuler E; Jansen R; Ledley FD; Zwelling LA
    Cancer Res; 1991 Sep; 51(17):4729-31. PubMed ID: 1651812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions.
    Zwelling LA; Mayes J; Hinds M; Chan D; Altschuler E; Carroll B; Parker E; Deisseroth K; Radcliffe A; Seligman M
    Biochemistry; 1991 Apr; 30(16):4048-55. PubMed ID: 1850298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase.
    Lefevre D; Riou JF; Ahomadegbe JC; Zhou DY; Benard J; Riou G
    Biochem Pharmacol; 1991 Jun; 41(12):1967-79. PubMed ID: 1645555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
    Zwelling LA; Mitchell MJ; Satitpunwaycha P; Mayes J; Altschuler E; Hinds M; Baguley BC
    Cancer Res; 1992 Jan; 52(1):209-17. PubMed ID: 1309224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquisition of multiple copies of a mutant topoisomerase IIalpha allele by chromosome 17 aneuploidy is associated with etoposide resistance in human melanoma cell lines.
    Campain JA; Slovak ML; Schoenlein PV; Popescu NC; Gottesman MM; Pastan I
    Somat Cell Mol Genet; 1995 Nov; 21(6):451-71. PubMed ID: 8600572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Further characterization of an amsacrine-resistant line of HL-60 human leukemia cells and its topoisomerase II. Effects of ATP concentration, anion concentration, and the three-dimensional structure of the DNA target.
    Mayes J; Hinds M; Soares L; Altschuler E; Kim P; Zwelling LA
    Biochem Pharmacol; 1993 Aug; 46(4):699-707. PubMed ID: 8395843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells.
    Bakic M; Chan D; Andersson BS; Beran M; Silberman L; Estey E; Ricketts L; Zwelling LA
    Biochem Pharmacol; 1987 Dec; 36(23):4067-77. PubMed ID: 2825713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha.
    Herzog CE; Holmes KA; Tuschong LM; Ganapathi R; Zwelling LA
    Cancer Res; 1998 Dec; 58(23):5298-300. PubMed ID: 9850052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II.
    Lee MS; Wang JC; Beran M
    J Mol Biol; 1992 Feb; 223(4):837-43. PubMed ID: 1311390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered phosphorylation, biosynthesis and degradation of the 170 kDa isoform of topoisomerase II in amsacrine-resistant human leukemia cells.
    Ganapathi R; Zwelling L; Constantinou A; Ford J; Grabowski D
    Biochem Biophys Res Commun; 1993 May; 192(3):1274-80. PubMed ID: 8389546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance.
    Baguley BC; Holdaway KM; Fray LM
    J Natl Cancer Inst; 1990 Mar; 82(5):398-402. PubMed ID: 2154584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) or 4-(4,6-O-ethylidene-beta-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells to the drugs.
    Estey EH; Silberman L; Beran M; Andersson BS; Zwelling LA
    Biochem Biophys Res Commun; 1987 Apr; 144(2):787-93. PubMed ID: 3034264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
    Prost S; Riou G
    Biochem Pharmacol; 1994 Aug; 48(5):975-84. PubMed ID: 8093110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA.
    Fernandes DJ; Danks MK; Beck WT
    Biochemistry; 1990 May; 29(17):4235-41. PubMed ID: 2163274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of polyamine depletion by alpha-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells.
    Bakic M; Chan D; Freireich EJ; Marton LJ; Zwelling LA
    Cancer Res; 1987 Dec; 47(24 Pt 1):6437-43. PubMed ID: 2824033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
    Ellis AL; Nowak B; Plunkett W; Zwelling LA
    Cancer Chemother Pharmacol; 1994; 34(3):249-56. PubMed ID: 8004759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
    Ling YH; Andersson BS; Nelson JA
    Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein.
    Granzen B; Graves DE; Baguley BC; Danks MK; Beck WT
    Oncol Res; 1992; 4(11-12):489-96. PubMed ID: 1363724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.